Matrixx Initiatives ups its buyout offer for ProPhase Labs (PRPH) by 14% to $1.60/share in cash...

|About: ProPhase Labs, Inc. (PRPH)|By:, SA News Editor

Matrixx Initiatives ups its buyout offer for ProPhase Labs (PRPH) by 14% to $1.60/share in cash from its earlier offer of $1.40 that PRPH had rejected. Matrixx is a private firm that makes Zicam cold medicine, a competitor to PRPH's Cold-Eeze product line.